- 4009 Hackney Springs Ln, Sachse, TX 75048
Hawaii molecular labs billing Medicare face steep compliance hurdles. Missing or invalid Z‑Codes, claims released before MolDX Technical Assessment approval, unbundled genomic panels, and expanded infectious disease panels ordered without an appropriate specialist can all trigger claim denials. Strict LCDs L39001 and L39230 add further documentation requirements.
To stay compliant, labs must automate Z‑Code population from the LIS, enforce a hold‑and‑release workflow tied to TA status, bill comprehensive genomic profiling as one test, and build front‑end ordering provider edits. A Hawaii‑based lab billing partner that specializes in MolDX and Noridian JE rules can embed these safeguards into daily operations, manage TA timelines, and ensure clean claims submission, so your team can focus on testing while securing full reimbursement.
If you run a lab in Hawaii and bill Medicare for molecular tests, it isn’t simple to run the assay and send a claim. If you miss a digit on a DEX Z-Code, your claim gets denied, and you risk losing your reimbursement, or at least experience a payment delay. It’s common for laboratories across the state, but it’s avoidable.
Once you understand how Noridian JE, MolDX, and the DEX registry fit together, the whole process gets a lot easier. Here, we’ll discuss the Noridian JE MolDX DEX Z-Code requirements for Hawaii labs to submit claims for infectious disease and genomic panels, and how best practices, such as getting professional Hawaii laboratory billing services, help you not just submit clean claims, but also recover revenue for each sample collected.
Hawaii is part of Medicare Administrative Contractor (MAC) Jurisdiction E (JE), which Noridian Healthcare Solutions administers. JE also covers California, Nevada, American Samoa, Guam, and the Northern Mariana Islands. Under Noridian, this jurisdiction participates fully in the MolDX (Molecular Diagnostic Services) program.
Any molecular diagnostic test you bill to Medicare in Hawaii, whether it’s an infectious disease panel or a comprehensive genomic profile, needs a valid DEX Z-Code attached to the claim.
Z-Code is a five-character fingerprint for your test. It tells the payer exactly which proprietary assay or lab-developed test (LDT) you ran, since standard CPT codes alone can’t capture that level of detail. You register the test through the DEX Diagnostics Exchange, managed by Palmetto GBA on behalf of the MolDX program, and once approved, you’ll get your identifier to submit claims back in roughly two weeks.
| Panel Type | Pathogen Count | Typical Billing Consideration |
|---|---|---|
| Targeted Panel | Up to 5 pathogens | Generally follows standard CPT coding, fewer specialist edit flags |
| Expanded Panel | 6 or more pathogens | Higher scrutiny, may require Z-Code and Technical Assessment if outside FDA labeling |
The reason is that expanded panels attract closer review from MolDX auditors, especially when they’re ordered outside the patient population the FDA label actually covers. If your lab runs a 12-target respiratory panel on every patient, regardless of symptoms or a specialist referral, that’s a denial.
Now, if your test has FDA clearance and you’re using it exactly as labeled, and there’s a matching ICD-10 code in the Billing and Coding Article, you can often submit claims without going through the full Technical Assessment. But once you step outside labeled use, or the test lacks its own proprietary code, registration and a technical assessment become mandatory.
Now let’s turn to the other big compliance focus for 2026, and that’s genomic panels. This covers Next-Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP) for solid tumors and blood cancers alike. The active policy here, L39230, deals specifically with plasma-based genomic profiling, otherwise known as liquid biopsy testing.
Under L39230, Guardant360® was the original benchmark assay for this policy, and other liquid biopsy tests get covered when they show similar performance for the same intended use. If tissue-based CGP is not feasible or has already returned no actionable findings, that opens the door to plasma testing instead.
Here’s something very important for lab billers.
Registering for a Z-Code is only step one. The Technical Assessment, or TA, is the real step you have to clear before Medicare reimburses your amount.
During the TA, MolDX reviewers review your published validation data and confirm its analytical validity, clinical validity, and clinical utility.
Analytical validity confirms if the test reliably detects what it claims to detect. Clinical validity makes sure that the mutation or pathogen is scientifically tied to the disease for which the test is being performed. And clinical utility confirms if the result is important in changing the way the patient gets treated.
And MolDX only reimburses tests performed on or after the date your technical assessment gets approved. Anything billed during that 60-day review window needs to be stored in your billing system.
| Claim Type | Form | Z-Code Location |
|---|---|---|
| Professional (Part B) | Electronic 837P | Line SV101-7 |
| Institutional (Part A) | UB-04 | Box 80 |
Pro tip: Just mention the Z-Code in the field. Don’t add extra digits or text to it. Noridian’s billing and coding guidance clearly mentions that the identifier should be mentioned alone and clean, right next to the CPT code.
To keep your molecular testing revenue safe, your lab must build safeguards right into its workflow.
Start by configuring your LIS and billing software to automatically append the correct five-character Z-Code on every claim, and set up clearinghouse edits that flag expanded infectious disease panels when the ordering provider isn’t an appropriate specialist like an infectious disease physician, pulmonologist, or gastroenterologist. You also need a hard hold-and-release workflow that stops any new or modified LDT claim from going out until the formal MolDX TA approval notice is in hand.
Pair that with a scheduled review cycle for the CMS Medicare Coverage Database, so your team never bills against outdated LCDs. Managing that detail alongside day-to-day tasks can overwhelm an in-house team. A Hawaii-based lab billing partner, like TransLabs, who knows the local payer landscape and MolDX requirements, can embed these checks directly into your daily operations, catching errors before claims ever leave your system and freeing your staff to focus on what they do best.
Compliance in the MolDX world isn’t just a one-time compliance requirement. It’s an ongoing discipline. Hawaii labs that master the Noridian JE Z-Code process, stay current on LCD L39001 and L39230, and build a process around the Technical Assessment keep their revenue secure.
Streamline your front-end verification process, train your ordering providers, and treat the TA review period with the patience it demands. With that, regulatory compliance isn’t a burden. It becomes a genuine edge for your revenue cycle, one that keeps clean claims flowing.